Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Addresses Calls To Publish COVID-19 Clinical Data

Executive Summary

The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.

You may also be interested in...



EMA To Publish All COVID-19 Clinical Data

The European Medicines Agency says the unprecedented public interest in treatments and vaccines being developed for COVID-19 has highlighted the need to provide access to more information than usual.

Coronavirus Notebook: EMA Focuses On EU Drug Supply Amid Fears Of Second Wave

In this latest update to coronavirus developments in the EU, the European Medicines Agency outlines plans to monitor demand for medicines in anticipation of a possible second wave of the COVID-19 pandemic later this year. It has also updated its adverse drug reaction literature monitoring service to cover potential coronavirus treatments, and backed the use of ACE-inhibitors and sartans during the pandemic.

‘Not Yet But Shortly’: EU Remdesivir Filing

The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel